<DOC>
	<DOCNO>NCT00987558</DOCNO>
	<brief_summary>The primary objective investigate whether multiple-dose administration ESL 800 mg daily affect pharmacokinetics simvastatin , substrate CYP34A .</brief_summary>
	<brief_title>Effect Repeated Administration Eslicarbazepine Acetate Pharmacokinetics Simvastatin Healthy Subjects</brief_title>
	<detailed_description>This single centre , two-way crossover , randomise , open-label study 24 healthy volunteer . The volunteer receive oral single-dose simvastatin 80 mg two occasion ─ administer alone treatment oral once-daily dose 800 mg ESL 14 day ─ , separate washout period 3 week</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive Body mass index ( BMI ) 18 30 kg/m2 , inclusive Healthy determine prestudy medical history , physical examination , vital sign , 12lead ECG ; negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screening ; clinical laboratory test result clinically acceptable screen admission treatment period ; Negative screen alcohol drug abuse screen admission treatment period Nonsmokers exsmokers Able willing give write informed consent ; If female , childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier method : 1 male barrier method [ male condom ] plus 1 female barrier method ( diaphragm , spermicide , intrauterine device ) ; If female , negative urine pregnancy test screen admission treatment period . Clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder Clinically relevant surgical history ; History relevant atopy drug hypersensitivity ( include know hypersensitivity ESL carboxamide derivative , simvastatin statin excipients History fibromyalgia , myopathy , rhabdomyolysis unexplained muscle pain Second thirddegree atrioventricular blockade correct pacemaker clinically significant abnormality 12lead electrocardiogram ( ECG ) determine investigator History alcoholism drug abuse Consume 14 unit alcohol week Significant infection know inflammatory process screen admission treatment period Acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period Use medicine within two week admission first period may affect safety study assessment , investigator 's opinion Have donate receive blood blood product within 3 month prior screen Vegetarians , vegan medical dietary restriction Can communicate reliably investigator Unlikely cooperate requirement study Unwilling unable give write informed consent If female , pregnant breastfeeding If female , childbearing potential use approve effective contraceptive method ( doublebarrier method : 1 male barrier method [ male condom ] plus 1 female barrier method ( diaphragm , spermicide , intrauterine device ) use hormonal contraceptive Have receive investigational drug within 3 month screen currently participate another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Eslicarbazepine acetate</keyword>
	<keyword>simvastatin</keyword>
</DOC>